About: Response to Letter: “Reply to ‘High frequency of Antiphospholipid Antibodies in Critically‐ill COVID19 patients: a Link with Hypercoagulability?’”

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Response to Letter: “Reply to ‘High frequency of Antiphospholipid Antibodies in Critically‐ill COVID19 patients: a Link with Hypercoagulability?’” Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Response to Letter: “Reply to ‘High frequency of Antiphospholipid Antibodies in Critically‐ill COVID19 patients: a Link with Hypercoagulability?’”
Creator	Combes, Alain Amoura, ; Frere, Corinne Hekimian, Guillaume Martin-Toutain, Isabelle Mathian, Alexis Miyara, Makoto Pineton De Chambrun, Marc
source	Medline; PMC
abstract	We read with great interest the comment by Suarez‐Perez et al. on our article.[1] We share their concerns regarding the need for a cautious interpretation of antiphospholipid antibodies (aPLA) positivity in patients with coronary virus disease 2019 (COVID‐19). Herein, we would like to add further insights in the discussion.
has issue date	2020-08-09(xsd:dateTime)
bibo:doi	10.1111/joim.13166
bibo:pmid	32772406
has license	no-cc
sha1sum (hex)	630dfacd5bfa69b5ab755963e3ea385538e2ee3d
schema:url	https://doi.org/10.1111/joim.13166
resource representing a document's title	Response to Letter: “Reply to ‘High frequency of Antiphospholipid Antibodies in Critically‐ill COVID19 patients: a Link with Hypercoagulability?’”
has PubMed Central identifier	PMC7436493
has PubMed identifier	32772406
schema:publication	J Intern Med
resource representing a document's body	covid:630dfacd5bfa69b5ab755963e3ea385538e2ee3d#body_text
is schema:about of	named entity 'Antibodies' named entity 'High frequency' named entity 'COVID19' named entity 'unfractionated heparin' named entity 'COVID' named entity 'false-positive' named entity 'aPLA' named entity 'COVID-19 disease' named entity 'C-reactive protein' named entity 'COVID' named entity 'COVID' named entity 'phospholipids' named entity 'aPLA' named entity 'sample size' named entity 'aPLA' named entity 'coagulation factor' named entity 'molecular mimicry' named entity 'virus disease' named entity 'thrombotic events' named entity 'antibodies' named entity 'COVID-19' named entity 'COVID' named entity 'acute infection' named entity 'coagulation tests' named entity 'phospholipid' named entity 'coagulation tests' named entity 'COVID' named entity 'antiphospholipid antibodies' named entity 'autoantibodies' named entity 'C-reactive protein' named entity 'phospholipids' named entity 'COVID-19' named entity 'autoimmune' named entity 'SARS-CoV-2' named entity 'viral infections' named entity 'cumulative incidence' named entity 'false positive' named entity 'cross-reactivity' named entity 'aPLA' named entity 'COVID-19' named entity 'anti-cardiolipin' named entity 'IgG' named entity 'autoimmune diseases' named entity 'heparin' named entity 'negatively charged' named entity 'coagulation factors' named entity 'aPLA' named entity 'PF4' named entity 'Antiphospholipid Antibodies' named entity 'Hypercoagulability' named entity 'LETTER' named entity 'patients' named entity 'Reply' named entity 'Response' named entity 'Letter' named entity 'High frequency' named entity 'Link' named entity 'Hypercoagulability' named entity 'LINK' named entity 'PATIENTS' named entity 'RESPONSE TO' named entity 'FREQUENCY' named entity 'ILL' named entity 'HYPERCOAGULABILITY' named entity 'COVID19' named entity 'ANTIPHOSPHOLIPID ANTIBODIES'
is part of of	covid:630dfacd5bfa69b5ab755963e3ea385538e2ee3d#body_text Response to Letter: “Reply to ‘High frequency of Antiphospholipid Antibodies in Critically‐ill COVID19 patients: a Link with Hypercoagulability?’” We read with great interest the comment by Suarez‐Perez et al. on our article.[1] We share their concerns regarding the need for a cautious interpretation of antiphospholipid antibodies (aPLA) positivity in patients with coronary virus disease 2019 (COVID‐19). Herein, we would like to add further insights in the discussion.

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software